The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...

The issuer is solely responsible for the content of this announcement.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Eli Lilly & Co. (NYSE: LLY) launched its own GLP-1/GIP dual agonist treatment for obesity, Zepbound, in December 2023. Zepbound is the most effective FDA-approved GLP-1 drug for weight loss.

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated ...